TOKYO, Oct. 21, 2014 (GLOBE NEWSWIRE) -- UBIC, Inc. (Nasdaq:UBIC) (TSE:2158) ("UBIC" or "the Company"), a leading provider of international litigation support and big-data analysis services, announced today that the Company will enter into the pharmaceutical big data analysis business leveraging its internally-developed, AI-based "Virtual Data Scientist" software program.
A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=28480
Solutions provided through this new business will make it possible to comprehensively analyze a variety of structured and unstructured data, ranging from genetic information to data from medical examinations and questionnaires. This development will improve the efficacy of measuring and analyzing the observations in clinical trials conducted for the development of new drugs.
In order to strengthen the Company's R&D methodology for pharmaceutical data analysis solutions and to accelerate related R&D initiatives, UBIC has appointed Masahiro Takeuchi, a professor of biostatistics and pharmaceutical medicine at Kitasato University, as a technical advisor with a focus on medical and pharmaceutical analysis.
To effectively analyze pharmaceutical information, it is essential to comprehensively analyze structured data, such as genetic information or data regarding vital signs and blood test information, as well as unstructured data, such as the results of questionnaires and examinations given by doctors.
UBIC's technology will improve the accuracy and efficiency of measuring and analyzing observations in clinical trials by leveraging the Company's know-how regarding the analysis of unstructured data that it has acquired through R&D which previously targeted discovery-related technologies in the fields of international litigation support and digital forensics. UBIC's know-how will help to better reconcile the diagnostic results given by doctors with observed variations in the effectiveness of certain drugs, in order to streamline the analysis of clinical trial data. Professor Takeuchi will utilize his many years of experience analyzing clinical trial data to advise UBIC on exploring medical and pharmaceutical applications for the company's existing technologies and implementing technical improvements.
The Company's R&D activities for medical data analysis solutions will be conducted by UBIC's Behavior Informatics Laboratories.
The biography of Professor Takeuchi follows.
Professor of clinical medicine at Kitasato University's School of Pharmacy (clinical statistics and pharmaceutical development) Doctor of science (biostatistics)
|November 1991:||Obtained an Sc.D. degree in Biostatistics from Harvard University's School of Public Health.|
|December 1991:||Joined the U.S. Food and Drug Administration (FDA) and worked as a mathematical statistician at the Center for Drug Evaluation and Research's Division of Biometrics. Oversaw drug treatment for cancer and Alzheimer's disease. Also served as a consultant for statisticians at the FDA.|
|April 1999:||Opened the clinical statistics division at Kitasato University's School of Pharmacy and served as a professor|
|April 2002:||Concurrently served as director of the Research Center for Clinical Pharmacology at the Kitasato Institute|
|April 2006:||Opened the pharmaceutical development division at Kitasato University's School of Pharmacy and served as a professor|
|April 2008:||Assumed current professorship following the integration of Kitasato University and the Kitasato Institute|
Professor Takeuchi's other duties and accomplishments include: a deputy directorship at the Kitasato Clinical Research Center; visiting professorship at Keio University's School of Medicine; advisory expert membership at the Ministry of Health, Labour and Welfare's Pharmaceutical Affairs and Food Sanitation Council; and committee memberships related to the Ministry of Education, Culture, Sports, Science and Technology, the Japan Science and Technology Agency, the Japan Surgical Society, the Japan Society of Clinical Oncology, the Japan Clinical Cancer Research Organization, the Japanese Gynecologic Oncology Group, the Japanese Center of Pharmaceutical Medicine, and the Tokyo Cooperative Oncology Group.
He also serves as an editor of "Clinical Education" and an associate editor of the Journal of Biopharmaceutical Statistics.
Behavior Informatics Laboratories:
UBIC's Behavior Informatics Laboratories is responsible for UBIC's R&D activities related to big data analysis and AI technologies based on behavior informatics. Behavior informatics is a science that views big data as an accumulation of patterns of human thinking and behavior and seeks to discover human truths from among the mass body of data by leveraging information sciences (statistics and IT) and behavioral sciences (criminology, psychology, sociology, etc.). The Behavior Informatics Laboratories conducts research on natural language processing, data mining and the development of software programs. At the same time, it feeds back knowledge acquired while conducting its service operations for clients to further support its own R&D activities and improve its software programs. Another prominent feature of the Behavior Informatics Laboratories is that it expedites the R&D cycle by simultaneously conducting both basic and applied research.
AI technologies developed by the Behavior Informatics Laboratories are intended to help promote safety and security through their application in UBIC's new business fields, including medical care, insider trading prevention, intellectual property assessment, and business intelligence.
UBIC, Inc. (Nasdaq:UBIC) (TSE:2158) is a leading provider of e-discovery and digital forensic services for Asia and the world. UBIC has extensive experience working with electronically stored information composed in Chinese, Japanese and Korean (CJK) languages and utilizes that expertise for clients involved in cross-border litigation, corporate investigations, intellectual property disputes and much more. At the forefront of e-discovery innovation, UBIC's proprietary Lit i View® platform is moving the industry from "fact discovery" to "future discovery" by allowing clients to analyze e-mail messages and digital communications found in big-data to reveal patterns in human thought and behavior.
Safe Harbor Statement
This announcement contains forward-looking statements. These forward-looking statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the amount of data that UBIC expects to manage this year and the potential uses for UBIC's new service in intellectual property-related litigation, contain forward-looking statements. UBIC may also make written or oral forward-looking statements in its reports filed with, or furnished to, the U.S. Securities and Exchange Commission, in its annual reports to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about UBIC's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: UBIC's goals and strategies; UBIC's expansion plans; the expected growth of the data center services market; expectations regarding demand for, and market acceptance of, UBIC's services; UBIC's expectations regarding keeping and strengthening its relationships with customers; UBIC's plans to invest in research and development to enhance its solution and service offerings; and general economic and business conditions in the regions where UBIC provides solutions and services. Further information regarding these and other risks is included in UBIC's reports filed with, or furnished to the Securities and Exchange Commission. UBIC does not undertake any obligation to update any forward-looking statement, except as required under applicable law. All information provided in this press release and in the attachments is as of the date of this press release, and UBIC undertakes no duty to update such information, except as required under applicable law.
CONTACT: Sasha Hefler UBIC North America, Inc. Tel: (650) 868-2623 email@example.com